AAPL 234.88 -1.257% MSFT 426.35 0.0094% NVDA 137.3 0.778% GOOGL 194.33 -0.6239% GOOG 195.93 -0.533% AMZN 222.83 -0.2328% META 612.7488 -0.7083% AVGO 235.305 3.2039% TSLA 416.28 -2.7883% TSM 217.5 5.1741% LLY 748.845 0.2819% V 318.02 0.5501% JPM 256.24 1.5415% UNH 526.4 -3.132% NVO 82.465 -0.5487% WMT 90.24 -1.2043% LVMUY 140.5 7.4488% XOM 111.18 -0.2959% LVMHF 703.0 7.5944% MA 523.165 0.156%
Last update at 2025-01-16T14:55:00Z
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Sun 15 Sep 24, 11:21 AM3 Biotech Stocks That Could Have Investors Grinning Soon
Fri 02 Aug 24, 05:54 PMCan These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Sat 20 Jul 24, 01:30 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -59.98700M | -49.65000M | -39.75800M | -68.83900M | -18.08500M |
Minority interest | - | 0.00000M | 0.52M | 14.12M | 14.32M |
Net income | -60.34500M | -50.15800M | -40.57100M | -68.81900M | -17.71100M |
Selling general administrative | 22.41M | 19.55M | 9.00M | 8.66M | 3.90M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | - | 1.00M | - | - | - |
Reconciled depreciation | 1.03M | 0.51M | 0.39M | 0.20M | 0.07M |
Ebit | -63.06100M | -50.37200M | -37.02500M | -70.19700M | -18.45500M |
Ebitda | -62.02900M | -49.86000M | -36.63100M | -70.00200M | -18.39000M |
Depreciation and amortization | 1.03M | 0.51M | 0.39M | 0.20M | 0.07M |
Non operating income net other | 2.04M | - | - | - | - |
Operating income | -62.02900M | -49.86000M | -37.02500M | -70.19700M | -18.45500M |
Other operating expenses | 62.03M | 50.86M | 37.02M | 70.20M | 18.45M |
Interest expense | -2.04200M | 0.72M | 2.21M | 1.57M | 0.00000M |
Tax provision | 0.36M | 0.51M | 0.81M | -0.02000M | -0.06700M |
Interest income | 2.11M | 0.17M | 0.06M | 1.20M | 0.33M |
Net interest income | 2.11M | 0.17M | 0.06M | 1.20M | 0.33M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 0.36M | 0.51M | 0.81M | -0.02000M | -0.06700M |
Total revenue | 0.00000M | 1.00M | 0.00000M | 0.00000M | 0.00000M |
Total operating expenses | 62.03M | 50.86M | 37.02M | 70.20M | 18.45M |
Cost of revenue | - | - | - | - | - |
Total other income expense net | 2.04M | 0.21M | -2.73300M | 1.36M | 0.04M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -60.34500M | -50.15800M | -40.57100M | -68.81900M | -18.01800M |
Net income applicable to common shares | -60.34500M | -50.15800M | -29.35200M | -68.61100M | -17.71100M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 268.52M | 287.03M | 168.07M | 92.29M | 23.90M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 3.99M | 2.07M | 0.95M | 0.33M | 0.46M |
Total liab | 13.15M | 10.08M | 7.77M | 23.70M | 19.70M |
Total stockholder equity | 255.37M | 276.94M | 160.30M | 68.59M | 4.21M |
Deferred long term liab | - |